Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec;29(6):583-92.

Antitubercular drug resistance in four healthcare facilities in North India

Anamika Gupta  1 , Jitendra Prasad Mathuria, Surya Kumar Singh, Anil Kumar Gulati, Shampa Anupurba
Affiliations

Antitubercular drug resistance in four healthcare facilities in North India

Anamika Gupta et al. J Health Popul Nutr. 2011 Dec.

Abstract

Tuberculosis (TB) is a major public-health problem in India, having the highest number of incident and multidrug-resistant (MDR) TB cases. The study was carried out to appraise the prevalence of first-line anti-TB drug resistance in Mycobacterium tuberculosis (MTB) and its patterns among different types of TB patients from different settings in a province of North India. Of 3,704 clinical specimens, 345 (9.3%) were culture-positive, and drug-susceptibility testing was carried out for 301 MTB strains. A high level of primary and acquired drug resistance of MTB was observed in the region studied, with weighted mean of 10.5% and 28.08%, 12.81% and 29.72%, 17.12% and 29.94%, 11.97% and 27.84%, and 10.74% and 23.54% for rifampicin, isoniazid, streptomycin, ethambutol-resistant and MDR cases respectively. Drug resistance was significantly higher in pulmonary (p = 0.014) and acquired drug-resistant TB cases (p < 0.001). Any drug resistance (p = 0.002) and MDR TB were significantly (p = 0.009) associated with HIV-seropositive cases. An urgent plan is needed to continuously monitor the transmission trends of drug-resistant strains, especially MDR-TB strains, in the region.

PubMed Disclaimer

Figures

Fig.
Fig.
Results of drug-susceptibility testing for individual antitubercular drugs and MDR-TB cases
See this image and copyright information in PMC

References

    1. Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet. 2006;368:2142–54. - PubMed
    1. World Health Organization . Stop TB partnership, 2009 update: tuberculosis facts. Geneva: World Health Organization; 2009. p. 1. ( http://www.who.int/tb/publications/2009/tbfactsheet_2009update_one_page.pdf, accessed on 15 December 2009).
    1. World Health Organization . Global tuberculosis control: epidemiology, strategy, financing. Geneva: WorldHealth Organization,; 2009. p. 78. (WHO report no. HTM/TB/2009.411).
    1. World Health Organization . TB/HIV: a clinical manual. Geneva: World Health Organization,; 2004. p. 210. ( http://libdoc.who.int/publications/2004/9241546344.pdf, accessed on 25 May 2008).
    1. Swaminathan S, Ramachandran R, Baskaran G, Paramasivan CN, Ramanathan U, Venkatesan P, et al. Risk of development of tuberculosis in HIV infected patients. Int J Tuberc Lung Dis. 2000;4:839–44. - PubMed

MeSH terms

Substances

LinkOut - more resources